[ Price : $8.95]
A Hyman, Phelps & McNamara statistical analysis of FDA Warning Letters published by FDLI shows that nearly three-quarters of Warni...[ Price : $8.95]
AstraZeneca says its investigational drug baxdrostat met the primary endpoint in the Phase 3 Bax24 trial in patients with resistan...[ Price : $8.95]
Thirteen Republican House members call on HHS to lay off the CDER director, Office of Generic Drugs director, and others who were ...[ Price : $8.95]
FDA clears restart of a pivotal clinical trial evaluating the NobleStitch EL system, a device-free, suture-mediated method for clo...[ Price : $8.95]
FDA approves a Boehringer Ingelheim NDA for Jascayd (nerandomilast) tablets for treating idiopathic pulmonary fibrosis.[ Price : $8.95]
FDA warns West Palm Beach, FL-based Technological Medical Advancement about Quality System violations in its production of two una...[ Price : $8.95]
FDA warns Santa Fe Springs, CA-based Creative Essences about CGMP violations in its production of misbranded unapproved drugs.[ Price : $8.95]
FDA input offers Lexeo Therapeutics a potential accelerated approval pathway for its investigational gene therapy LX2006.